Silence Therapeutics
34 hedge funds and large institutions have $344M invested in Silence Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
102% more capital inflows, than outflows
Capital inflows: $19M | Capital outflows: $9.42M
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
21% more funds holding
Funds holding: 28 → 34 (+6)
0.55% less ownership
Funds ownership: 53.67% → 53.12% (-0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vivo Capital
Palo Alto,
California
|
+$5.73M |
| 2 |
AG
Artal Group
Luxembourg
|
+$5.61M |
| 3 |
Logos Global Management
San Francisco,
California
|
+$4.49M |
| 4 |
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
+$1.9M |
| 5 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$450K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$3.02M |
| 2 |
Goldman Sachs
New York
|
-$2.62M |
| 3 |
Lombard Odier Asset Management (USA)
New York
|
-$2.01M |
| 4 |
Woodline Partners
San Francisco,
California
|
-$1.32M |
| 5 |
Cantor Fitzgerald
New York
|
-$240K |
SLN Hedge Fund Activity: Q4 2023 in Review
34 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2023, worth a combined $344M — up 83% from $188M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SLN positions and 2 closed out — a net gain of 6 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $5.73M. The largest seller was Aquilo Capital Management, cutting an estimated $3.02M.
- 34 institutional investors held Silence Therapeutics (SLN) as of Q4 2023, up from 28 in Q3 2023.
- Funds reported $344M of Silence Therapeutics stock for Q4 2023, up 83% quarter-over-quarter.
- 8 funds opened new Silence Therapeutics positions in Q4 2023 and 2 closed out, a net change of +6 holders.
- The largest Silence Therapeutics buyer in Q4 2023 was Vivo Capital, an estimated $5.73M added.
- The largest Silence Therapeutics seller in Q4 2023 was Aquilo Capital Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2023.